Surmodics stock rises after FTC indicates no appeal of merger ruling By Investing.com
Surmodics stock rises after FTC indicates no appeal of merger ruling
Surmodics stock rises after FTC indicates no appeal of merger ruling
Surmodics reports June cyber incident, restores critical IT systems
SurModics (SRDX) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates for some clues.
Despite the strength in Pounce thrombectomy device platforms and strong IVD product sales, Surmodics second-quarter fiscal 2025 results show weak performance.